Less than 1 min.Read

MGC Pharmaceuticals: Completes COVID-19 phase two test

November 5, 2020

MGC Pharmaceuticals (MXC) has completed its COVID-19 phase two clinical trial
The trial saw 50 virus-infected patients treated with MGC’s anti-inflammatory treatment, ArtemiC
Then the aim of the trial was to test the efficacy and safety of the treatment and evaluate the patient’s recovery rates
Results of the trial will reported in the next month following an independent technical review and statistical validation of the trial data
The second wave of the pandemic is again putting increased pressure on a number of healthcare systems around the world
On the market this afternoon, MGC is up 10 per cent and is trading for 2.2 cents per share